Serum Osteoprotegerin Levels Are Increased in Patients with Advanced Prostate Cancer

• Published in: Clinical cancer research 2001-10, Vol.7 (10), p.2977-2983
• Main Authors: BROWN, Julie M, VESSELLA, Robert L, KOSTENUIK, Paul J, DUNSTAN, Colin R, LANGE, Paul H, COREY, Eva
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Biological and medical sciences; Bone Neoplasms - blood; Bone Neoplasms - secondary; Collagen - blood; Enzyme-Linked Immunosorbent Assay; Glycoproteins - blood; Humans; Male; Medical sciences; Middle Aged; Neoplasm Recurrence, Local - blood; Neoplasm Recurrence, Local - pathology; Nephrology. Urinary tract diseases; Osteoprotegerin; Peptide Fragments - blood; Prostatic Hyperplasia - blood; Prostatic Hyperplasia - pathology; Prostatic Neoplasms - blood; Prostatic Neoplasms - pathology; Receptors, Cytoplasmic and Nuclear - blood; Receptors, Tumor Necrosis Factor; Tumors of the urinary system; Urinary tract. Prostate gland
• ISSN: 1078-0432; 1557-3265

Purpose: Osteoprotegerin (OPG) is a soluble osteoclastogenesis inhibitor that regulates bone turnover. We reported recently that OPG protein expression is significantly increased in prostate cancer (CaP) cells present in bone metastases. The aim of this study was to determine serum OPG levels in patients at different stages of CaP and correlate the results with disease status. Experimental Design: OPG levels were examined in patients with benign prostatic hyperplasia, clinically localized CaP, early recurrence of CaP, and advanced CaP and evidence of bone metastases. Serum OPG levels were measured by sandwich ELISA assays. The serum Crosslaps (sCTX) assay was used to quantify bone resorption in the advanced CaP group. Results : Serum OPG levels were increased significantly in the advanced CaP group versus all other groups. There was no significant correlation between serum OPG levels and PSA levels either in the advanced CaP group or within any of three treatment subclasses of this group: no Tx, those not treated; Tx, those treated; and R, those treated with resorption blockers. Levels of OPG were negatively correlated with sCTX levels only in the advanced CaP Tx group. sCTX levels correlated with prostate-specific antigen levels in the advanced CaP Tx and R groups but not in the no-Tx group. Conclusions : Our data show that serum OPG levels are increased with advanced CaP. We hypothesize that OPG levels are related to CaP progression and suggest that further studies of the biological effects of OPG on CaP metastases are warranted.